Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

 Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

Shots:

  • Molecular Partners to receive $65.8M as up front, including equity, and will receive $164.7M as an option payment for both MP0420 and MP0423 along with royalties on sales of therapies. Novartis to get an option to in-license global rights of MP0420 and MP0423
  • During the option period, Molecular Partners will conduct a P-I study for MP0420, expected to initiate in Nov’2020, and perform all remaining preclinical work for MP0423 while Novartis will lead P-II & P-III study
  • Upon option exercise, Novartis will lead further development and commercialization activities while Molecular Partners will provide clinical supply during the development stage. MP0420 and MP0423 are potential medicines for the prevention & treatment of COVID-19, with the possibility of being manufactured at scale and the potential to bypass cold storage

Click here ­to­ read full press release/ article | Ref: Novartis | Image: M3 India

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post